[Correspondence] Rethinking atherosclerotic disease prevention

The Lancet Commission on rethinking coronary artery disease1 offers important advances in cardiovascular disease (CVD) prevention. The Commission argues, correctly in our opinion, that identification of adequate management of people with high blood pressure is more important than finding the optimal CVD risk threshold for its pharmacological treatment. A large (n=3 337 314) cross-sectional study of people aged 45–74 years in Australia2 showed that 41% of individuals with low CVD risk and blood pressure of more than 140/90 mm Hg were not managed with antihypertensive medications.